Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?
- PMID: 25332957
- PMCID: PMC4200636
- DOI: 10.3978/j.issn.2305-5839.2013.01.03
Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?
References
-
- Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. - PubMed
-
- Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-7. - PubMed
-
- De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62. - PubMed
-
- Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous